Good post by Walter Armstrong - "The Big Reset"
How come executives from drug or device manufacturers are never quoted in these articles? If "outcome-based" medicine is the way to go -- then current silos of the health care value chain will need to be taken apart. More vertical integration will be required -- from the manufacturer to patient -- so that efficacy can be measured and incentivized.
Also curious to hear how much money payors have been spending to maintain the status quo. I don't agree with Peter Tollman's comment: "The revenues of the industry haven't declined yet, but projections say they will. Growth rates have gone down significantly, so it's certainly not a growth industry anymore. That's a very long journey."Growth is stagnating because manufacturers have not figured out how to break through the current morass of globalization, patent cliff, price transparency, etc. As the population ages in the developed world, drug and device companies are facing a gold mine in the coming decades. Question is which ones will be visionary enough to put themselves in a position to capitalize.
More on this soon...
Subscribe to:
Post Comments (Atom)
Moving from volume to outcome-based reimbursements is a hot topic in Life Sciences. Regardless of whether current health care reform efforts succeed or fail, this is a subject that is not going away. Model N's Gop Rao covers it in a little more detail here: https://tw2l.market2lead.com/go/modeln/perspectives_rao
ReplyDelete